Davita Inc vs Target Corporation — how do they compare? Davita Inc trades at $178.5 (market cap $11.38B), while Target Corporation trades at $152.34 (market cap $69.17B). The key difference: Target Corporation is far larger — about 6.1× Davita Inc's market cap, and Target Corporation pays a 3.05% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | TGT | |
|---|---|---|
Market Cap | $11.38B | $69.17B |
Sector | Health | Consumer Cyclical |
52-Week High | $240.96 | $152.35 |
52-Week Low | $103.87 | $83.68 |
Enterprise Value | $24.10B | $84.47B |
Dividend Yield | — | 3.05% |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.69, down slightly by 0.04% over the past day. The stock shows strong fundamental performance with consistent earnings beats in recent quarters, including Q2 2026 EPS of $4.02 versus $3.88 expected (Zacks Investment Research, 2026-08-04). However, technical indicators signal a bearish trend, with the price near key support at $182. Revenue growth remains steady, climbing to $13.64 billion in 2025, though net income margin dipped to 5.47%.
The outlook is mixed; analyst consensus leans bullish with a $232.25 price target (MarketBeat, 2026-08-05), but risks include reimbursement pressure and high debt levels. Investment appeal hinges on execution against guidance amid payer-mix challenges, with the current valuation offering potential upside if operational trends stabilize.
Target (TGT) trades at $152.09, up 1.6% today and near its 52-week high, with a bullish technical outlook supported by moving averages. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 results pending. Valuation metrics show a P/E of 20.12 and P/S of 0.65, while profitability remains solid with a 22.02% ROE. Recent news highlights the appointment of a Chief AI Officer, signaling strategic focus on technology.
The outlook for TGT is positive, driven by earnings momentum and AI initiatives, but risks include competitive retail pressures and potential margin compression. Analyst consensus is mixed with a $147.72 price target, suggesting limited upside from current levels, though institutional buying activity supports bullish sentiment.
Trailing returns across standard periods
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →